Curated News
By: NewsRamp Editorial Staff
April 21, 2025
Quantum BioPharma Announces Corporate Updates and Debt Settlement
TLDR
- Quantum BioPharma (NASDAQ: QNTM) granted 60,000 restricted share units and authorized debt settlement with Class B Shares at $6.75.
- Quantum BioPharma focuses on innovative biotech solutions for neurodegenerative and metabolic disorders, including drug candidates in various stages of development.
- Quantum BioPharma's research aims to treat challenging disorders like multiple sclerosis, making significant strides in improving patients' quality of life.
- Quantum BioPharma's Lucid-MS compound shows promise in preventing myelin degradation, potentially revolutionizing multiple sclerosis treatment.
Impact - Why it Matters
This news matters as it showcases Quantum BioPharma's commitment to developing solutions for challenging disorders. The company's innovative approach and recent updates demonstrate its dedication to making a positive impact on healthcare.
Summary
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) recently announced corporate updates, including the grant of restricted share units and the settlement of outstanding debt. The company is dedicated to developing innovative assets for neurodegenerative and metabolic disorders.
Through its subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma focuses on the research and development of its lead compound, Lucid-MS, for multiple sclerosis. Additionally, the company invented UNBUZZD(TM) and spun out its OTC version to Celly Nutrition Corp., retaining ownership and receiving royalty payments.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Quantum BioPharma Announces Corporate Updates and Debt Settlement
